title: [The role of leptin, adiponectin and insulin-resistance markers in development of early stages of chronic kidney disease and atherosclerosis of carotid arteries in obese patients].
abstract: OBJECTIVE
  To characterize clinicopathogenetically factors influencing development of early chronic kidney disease (CKD) and impairment of other target organs in obese patients.
  
  
  METHODS
  The examination of 86 obese patients (64 males and 22 females, mean age 44 +/- 11 years) included standard clinical tests, test for albuminuria, calculation of glomerular filtration rate (GFR) by MDRD formula, ultrasound investigation of the carotid arteries to detect atherosclerotic lesion of the carotid arteries, assessment of insulin resistance - IR (plasma concentration of insulin before meal and blood C-peptide, HOMA-index), test for plasma adipokinins (leptin, adiponectin).
  
  
  RESULTS
  Significant direct correlations were found between blood plasma leptin concentration, body mass index (BMI), plasma concentration of insulin and C-peptide, HOMA index, adiponectinemia and albuminuria. CKD patients have significantly higher than patients free of CKD levels of IR markers, waist circumference, BMI, leptinemia (38.2 +/- 28.8 and 21.6 +/- 19.8 ng/ml, respectively; p < 0.01). Obstructive sleep apnea syndrome was associated with higher IR and albuminuria, significantly lower estimated GFR (81 +/- 2 and 95 +/- 2 ml/min/1.73 m2, respectively; p < 0.05). Ultrasound evidence for atherosclerotic lesions of the carotid arteries was associated with a significant increase in blood plasma concentration of C-peptide, reduction of adiponectinemia (14.9 +/- 10.8 and 32.5 +/- 22.5 mcg/ml; p < 0.01), a rise in proportion fasting insulinemia/adiponectinemia (1.6 +/- 1.2 and 0.6 +/- 0.8, respectively; p < 0.05) and reduction of estimated GFR (86 +/- 19 and 102 +/- 25 ml/min/1.73 m2, respectively; p = 0.001).
  
  
  CONCLUSIONS
  In obesity, CKD at early stages develops in parallel with atherosclerotic lesion of the carotid arteries, which correlates with progression of leptinemia, IR and attenuation of organ-protecting properties of adiponectin.
authors.forename: E A
authors.initials: EA
authors.lastname: Saginova
authors.forename: M G
authors.initials: MG
authors.lastname: Galliamov
authors.forename: M M
authors.initials: MM
authors.lastname: Severova
authors.forename: O A
authors.initials: OA
authors.lastname: Surkova
authors.forename: V V
authors.initials: VV
authors.lastname: Fomin
authors.forename: N V
authors.initials: NV
authors.lastname: Ermakov
authors.forename: A V
authors.initials: AV
authors.lastname: Rodina
authors.forename: N A
authors.initials: NA
authors.lastname: Mukhin
mesh_terms: D052242:Adiponectin / Q000097:blood / Q000378:metabolism*; D050197:Atherosclerosis / Q000209:etiology / Q000378:metabolism*; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D002340:Carotid Artery Diseases / Q000209:etiology / Q000378:metabolism*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D007674:Kidney Diseases / Q000209:etiology / Q000378:metabolism*; D020738:Leptin / Q000097:blood / Q000378:metabolism*; D008297:Male; D009765:Obesity / Q000097:blood / Q000150:complications*
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D020738:Leptin